Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension

Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension

(1) Background: Arterial hypertension (HTN) is one of the most relevant cardiovascular risk factors. Nowadays multiple pharmaceutical treatment options exist with novel interventional methods (e.g., baroreflex activation therapy (BAT)) as a last resort to treat patients with resistant HTN. Although...

Full description

Bibliographic Details
Main Authors: Mark Lipphardt, Hassan Dihazi, Jens-Holger Maas, Ann-Kathrin Schäfer, Saskia I. Amlaz, Brian B. Ratliff, Michael J. Koziolek, Manuel Wallbach
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Journal of Clinical Medicine
Subjects:
Syndecan-4
resistant hypertension
endothelium
baroreflex activation therapy
Online Access:https://www.mdpi.com/2077-0383/9/9/3051

Internet

https://www.mdpi.com/2077-0383/9/9/3051

Similar Items